Histogenics’ NeoCart Phase I/Phase II Clinical Trial Data

Results from Phase I and Phase II study indicate that Histogenics' NeoCart® tissue-engineered implant is a safe, effective treatment for articular cartilage lesions through 5-year follow-up. Further, patient-reported outcomes demonstrated statistically significant improvement on virtually all pain and functional endpoints, as early as 3 to 6...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us